An investigational treatment for Parkinson’s disease known as GT-02287 safely led to a roughly 53% increase in GCase enzyme activity, as measured in dried blood spots from treated healthy adults relative to those given a placebo in a Phase 1 clinical trial, its developer, Gain Therapeutics, reported. This…
News
People with Parkinson’s face risks during hospital stays, even when admitted for reasons other than the neurodegenerative disease itself, leading researchers to urge hospitals and health systems to adopt better practices, such as those recommended by the Parkinson’s Foundation. “Patients with Parkinson’s disease are at increased risk for…
ACI-7104, an investigational vaccine to treat people in the early stages of Parkinson’s disease, is showing safety and tolerability in a Phase 2 clinical trial, while also inducing the production of anti-alpha-synuclein antibodies at high levels, according to interim trial findings. Being developed by AC Immune,…
Crushed dried seeds of the jujube fruit, a traditional herbal medicine also known as Chinese or red date, eased the motor symptoms of Parkinson’s and helped with neurogenesis, the process by which new neurons are formed in the brain, in a mouse model of the disease. In a study led…
Vesalius Therapeutics has entered into an agreement with GSK to advance the development of new therapies for Parkinson’s disease and one other undisclosed neurodegenerative condition. Under the agreement, Vesalius will be responsible for identifying new treatment targets for the conditions, while GSK will have the option to…
The Critical Path Institute (C-Path) is launching a new initiative to advance research on how Parkinson’s disease impacts women and people across the gender spectrum. The goal is to develop treatments and technologies that take into account each person’s unique experience with the disease, leading to more equitable approaches for…
Higher levels of proteins called chaperones are linked with lower levels of disease-driving toxic protein clumps in the brains of people with Parkinson’s disease, a new study shows. The findings suggest that increasing chaperone proteins may be a viable therapeutic strategy for Parkinson’s. Data from the study also revealed…
Researchers have developed a method to detect clumps of alpha-synuclein protein, a hallmark of Parkinson’s disease, within extracellular vesicles (EVs) purified from blood, providing a possible aid to Parkinson’s diagnosis before symptoms appear. EVs are tiny membrane-bound sacs released from cells that can carry a variety of molecules, including…
People who received five or more courses of penicillin antibiotic treatment in the five years before a Parkinson’s diagnosis had an approximately 15% lower risk of developing the disease than those who took no antibiotics, according to a Rutgers Health study. Conversely, treatment with two or more courses of…
The planned Phase 2 SUNRISE-PD clinical trial of oral bezisterim as a first-line, stand-alone treatment for newly diagnosed Parkinson’s disease patients is scheduled to begin in early 2025. BioVie, the therapy’s developer, has secured over $15 million to cover complete costs of the trial, and top-line findings are…
Recent Posts
- New support group offers help, connection for Parkinson’s families
- Looking back at the changing roles and relationships in Parkinson’s
- Lab-made small molecule may help slow brain disease progression
- New report shows Parkinson’s costs surpass $82 billion in US in 2024
- Pushing forward this Parkinson’s Awareness Month with boldness, grace